Table 1.
Patient Characteristics
| Characteristic | No. (%) |
|---|---|
| Total | 350 |
| DFCI ALL consortium treatment protocol | |
| 95-01 | 209 (60) |
| 00-01 | 141 (40) |
| Age at initial diagnosis, years; median (range) | 4.2 (1-17.99) |
| < 5 | 210 (60) |
| 5-9.99 | 93 (27) |
| 10-17.99 | 47 (13) |
| Sex | |
| Female | 159 (45) |
| Male | 191 (55) |
| Risk group | |
| Standard risk | 225 (64) |
| High risk | 125 (36) |
| Race/ethnicity | |
| White | 308 (88) |
| Black or African American | 8 (2) |
| Asian | 6(2) |
| Other/unknown | 28 (8) |
| Hispanic | 25 (7) |
| CNS prophylaxis | |
| Intrathecal chemotherapy | 176 (50) |
| Cranial radiation (12 or 18 Gy) | 156 (45) |
| Not recorded/not given | 18 (5) |
| Corticosteroids | |
| Prednisone | 277 (79) |
| Dexamethasone | 73 (21) |
| None | 0 (0) |
| Age at time of neurocognitive testing, years; median (range) | 10 (6-25) |
| Years from diagnosis to testing, median (range) | 5 (3-9) |
| Mother's education | |
| High school graduate/GED or less | 89 (25) |
| Some college or more | 251 (72) |
| Unknown | 10 (3) |
NOTE. Demographic and treatment variables are shown for patients included in the genetic analyses.
Abbreviations: ALL, acute lymphoblastic leukemia; DFCI, Dana-Farber Cancer Institute; GED, general equivalency diploma.